BR112017013029A2 - síntese comercialmente viável de cantaridina e de-rivados de cantaridina bioativos - Google Patents

síntese comercialmente viável de cantaridina e de-rivados de cantaridina bioativos

Info

Publication number
BR112017013029A2
BR112017013029A2 BR112017013029A BR112017013029A BR112017013029A2 BR 112017013029 A2 BR112017013029 A2 BR 112017013029A2 BR 112017013029 A BR112017013029 A BR 112017013029A BR 112017013029 A BR112017013029 A BR 112017013029A BR 112017013029 A2 BR112017013029 A2 BR 112017013029A2
Authority
BR
Brazil
Prior art keywords
cantharidine
bioactive
commercially viable
viable synthesis
cantharidin derivatives
Prior art date
Application number
BR112017013029A
Other languages
English (en)
Other versions
BR112017013029B1 (pt
Inventor
Davidson Matthew
R Schow Steven
Original Assignee
Verrica Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56127857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017013029(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Verrica Pharmaceuticals Inc filed Critical Verrica Pharmaceuticals Inc
Publication of BR112017013029A2 publication Critical patent/BR112017013029A2/pt
Publication of BR112017013029B1 publication Critical patent/BR112017013029B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D497/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Catalysts (AREA)

Abstract

a presente revelação proporciona métodos para sintetizar cantaridina e derivados de cantaridina.
BR112017013029-7A 2014-12-17 2015-12-17 Processo para a preparação de cantaridina BR112017013029B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093396P 2014-12-17 2014-12-17
US62/093,396 2014-12-17
PCT/US2015/066487 WO2016100732A2 (en) 2014-12-17 2015-12-17 Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives

Publications (2)

Publication Number Publication Date
BR112017013029A2 true BR112017013029A2 (pt) 2018-01-09
BR112017013029B1 BR112017013029B1 (pt) 2022-12-06

Family

ID=56127857

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013029-7A BR112017013029B1 (pt) 2014-12-17 2015-12-17 Processo para a preparação de cantaridina

Country Status (12)

Country Link
US (2) US10745413B2 (pt)
EP (1) EP3233865A4 (pt)
JP (3) JP6810693B2 (pt)
KR (1) KR102528106B1 (pt)
CN (2) CN114106013A (pt)
AU (2) AU2015364524A1 (pt)
BR (1) BR112017013029B1 (pt)
CA (1) CA2971279C (pt)
HK (1) HK1246276A1 (pt)
IL (2) IL252907B2 (pt)
MX (2) MX2017008097A (pt)
WO (1) WO2016100732A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308690B2 (en) 2013-08-21 2019-07-18 Verrica Pharmaceuticals, Inc. Compositions, methods and systems for the treatment of cutaneous disorders
CN114106013A (zh) 2014-12-17 2022-03-01 维里卡制药有限公司 斑螯素和生物活性斑螯素衍生物的商业上可行的合成
US11168091B2 (en) 2015-01-20 2021-11-09 Verrica Pharmaceuticals Inc. Quantification and preparation of pharmaceutical grade cantharidin
CN106674248B (zh) * 2016-12-17 2019-02-26 重庆市中药研究院 一种斑蝥素的合成工艺
CA3065151A1 (en) 2017-06-06 2018-12-13 Verrica Pharmaceuticals Inc. Treatment of cutaneous disorders
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator
IL305371A (en) 2017-10-04 2023-10-01 Verrica Pharmaceuticals Inc Synthesis of cantharidin
WO2019086922A1 (en) * 2017-10-31 2019-05-09 Université de Bourgogne Therapeutical compositions for use in the treatment of non- malignant conditions associated with phosphatidylinositol-3- kinase activation: overgrowth spectrum, cutaneous capillary malformations and seborrheic keratoses
CN113455515A (zh) * 2021-06-24 2021-10-01 广东省农业科学院果树研究所 斑蝥素在制备防治柑橘采后绿霉菌的农药杀菌剂的应用
KR20240012182A (ko) 2022-07-20 2024-01-29 고려대학교 산학협력단 칸타리딘을 유효성분으로 포함하는 교모세포종 예방 또는 치료용 조성물

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4739621Y1 (pt) 1968-04-18 1972-11-30
US4148917A (en) 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
US4298752A (en) * 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JP3117502B2 (ja) 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
JPH05255367A (ja) * 1992-02-28 1993-10-05 Jitsuei O カンタリジン誘導体組成物の製造法及びそれを含む抗ウイルス剤
US5445462A (en) 1993-08-03 1995-08-29 Medi-Flex Hospital Products, Inc. Liquid applicator
AU7629694A (en) 1993-08-17 1995-03-14 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
US5590780A (en) 1995-06-22 1997-01-07 Wheaton Holding, Inc. Unit dose assembly
FR2754175B1 (fr) 1996-10-07 1999-07-02 Oreal Utilisation d'un organopolysiloxane de nature elastomerique associe a une phase organique dans un produit de demaquillage des ongles
US6030633A (en) 1998-05-18 2000-02-29 West Agro, Inc. Film-forming compositions for protecting animal skin
JPH11335303A (ja) 1998-05-26 1999-12-07 Lion Corp 苦味増強方法及び皮膚外用剤
US6337076B1 (en) 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US20030072814A1 (en) 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US20040152766A1 (en) * 2001-05-31 2004-08-05 Au-Yeung Steven C.F. Composition comprising demethylcantharidin in combination with platinum-containing anticancer agents and use thereof
US6899897B2 (en) 2001-06-18 2005-05-31 Jaleva, Inc. Gum resin as a carrier for topical application of pharmacologically active agents
US6673031B2 (en) 2001-09-25 2004-01-06 Phillip Mark Liquid applicator
PL210841B1 (pl) * 2001-10-19 2012-03-30 Isotechnika Inc Sposób wytwarzania mieszaniny izomerów (E) i (Z) ISATX247
JP2004059446A (ja) * 2002-07-25 2004-02-26 Mitsui Chemicals Inc 脂環式化合物及びその製造方法
WO2004093786A2 (en) 2003-04-16 2004-11-04 Corium International Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith
US20070111954A1 (en) 2003-07-23 2007-05-17 Cuticeuticals, Inc. Apparatus and method of wart treatment
US20050019418A1 (en) 2003-07-23 2005-01-27 Crutchfield Charles E. Wart treatment
JP2005187330A (ja) 2003-12-24 2005-07-14 Lion Corp 歯牙貼布用製品及びゲル組成物の選定方法
FR2865360B1 (fr) 2004-01-22 2006-05-26 Oreal Applicateur comportant un element d'application solidaire, lors de l'utilisation, d'un recipient contenant un produit a appliquer
FR2872704B1 (fr) * 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20050111900A1 (en) 2004-11-30 2005-05-26 Francesca Fazzolari Ampoule and method of use
FR2885779B1 (fr) 2005-05-23 2007-08-10 Oreal Dispositif de conditionnement et d'application d'un produit cosmetique ou dermatologique
US20070187437A1 (en) 2006-02-10 2007-08-16 Nordson Corporation Dispensing tip for liquid dispensing systems and method of making the same
JP5132071B2 (ja) 2006-03-31 2013-01-30 小林製薬株式会社 皮膚外用剤
DE102006034272A1 (de) 2006-07-18 2008-01-24 Aesculap Ag & Co. Kg Flüssigkeitsspender in der Medizin in Form einer Handhabe sowie dessen Verwendung
CN100465176C (zh) 2006-08-18 2009-03-04 芜湖天远科技开发有限责任公司 一种提取斑蝥素的方法
US20080146674A1 (en) 2006-12-15 2008-06-19 Rosenberg E William Use of gentian violet in treatment of atopic dermatitis
US8518076B2 (en) 2007-01-08 2013-08-27 Advanced Medical Solutions (Plymouth) Limited Surgical adhesive applicator
JP5230023B2 (ja) 2007-01-25 2013-07-10 ハイパーブランチ メディカル テクノロジー， インコーポレイテッド 複数成分製剤などのための塗布器および使用方法
CN101036774B (zh) 2007-04-17 2010-12-29 贵州益佰制药股份有限公司 一种复方斑蝥口服制剂的检测方法
CN101108853B (zh) 2007-07-27 2010-05-26 贵州大学 斑蝥素分离纯化方法
CN100577665C (zh) * 2007-08-16 2010-01-06 广东药学院 一种抗肿瘤活性斑蛰素衍生物及其制备方法
DE102007046600A1 (de) 2007-09-27 2009-04-02 Linhardt Metallwarenfabrik Gmbh & Co Kg Verfahren zum Applizieren eines flüssigen, medizinischen Behandlungsmediums auf einen zu behandelden Bereich sowie Medizinprodukt
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
JP5396125B2 (ja) 2009-03-30 2014-01-22 有限会社日本健康科学研究センター 被膜形成型製剤
KR101791705B1 (ko) 2009-10-08 2017-10-30 바이엘 컨수머 케어 악티엔게젤샤프트 저 에테르 조성물 및 전달 장치
US20120016320A1 (en) 2010-07-13 2012-01-19 Lin Michael T Method and Device for Liquid Delivery
US20120148520A1 (en) 2010-12-10 2012-06-14 Michael Strobel Organic Iodine Complex Durable Barrier With Antimicrobial Preparations
FR2972928B1 (fr) 2011-03-25 2013-11-29 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
CN102146086B (zh) 2011-04-12 2012-03-07 贵州金桥药业有限公司 一种斑蝥酸钠的制备方法
US20120312709A1 (en) 2011-04-12 2012-12-13 Velcera, Inc. Device for storing and dispensing a medicament, and packaging for containing the same
US9486829B2 (en) 2011-06-04 2016-11-08 Optmed, Inc. Applicator
CN102268006B (zh) 2011-06-15 2013-08-14 北京联合大学生物化学工程学院 一种复合酶提取斑蝥素的方法
US8871801B2 (en) 2011-08-01 2014-10-28 Jacob LEVITT Method of treating acquired perforating dermatosis with cantharidin
CN202920809U (zh) 2012-09-27 2013-05-08 合肥诚者成医药科技有限公司 一种治疗尖锐湿疣的软膏
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
AU2014308690B2 (en) 2013-08-21 2019-07-18 Verrica Pharmaceuticals, Inc. Compositions, methods and systems for the treatment of cutaneous disorders
CN103923095A (zh) * 2014-04-23 2014-07-16 遵义医学院 一种去甲基斑蝥素酸钙
WO2016061193A1 (en) 2014-10-15 2016-04-21 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
CN114106013A (zh) 2014-12-17 2022-03-01 维里卡制药有限公司 斑螯素和生物活性斑螯素衍生物的商业上可行的合成
US11168091B2 (en) 2015-01-20 2021-11-09 Verrica Pharmaceuticals Inc. Quantification and preparation of pharmaceutical grade cantharidin

Also Published As

Publication number Publication date
JP2021073173A (ja) 2021-05-13
IL274968A (en) 2020-07-30
EP3233865A4 (en) 2018-12-05
MX2017008097A (es) 2018-01-09
WO2016100732A3 (en) 2016-09-09
AU2015364524A1 (en) 2017-07-13
US20210070771A1 (en) 2021-03-11
AU2020244554B2 (en) 2022-10-20
EP3233865A2 (en) 2017-10-25
KR20170117027A (ko) 2017-10-20
IL252907B2 (en) 2023-08-01
JP2018500336A (ja) 2018-01-11
BR112017013029B1 (pt) 2022-12-06
HK1246276A1 (zh) 2018-09-07
CN107530322A (zh) 2018-01-02
KR102528106B1 (ko) 2023-05-03
IL252907A0 (en) 2017-08-31
CN107530322B (zh) 2021-10-15
US20190002474A1 (en) 2019-01-03
WO2016100732A2 (en) 2016-06-23
CA2971279A1 (en) 2016-06-23
CA2971279C (en) 2023-09-19
CN114106013A (zh) 2022-03-01
AU2020244554A1 (en) 2020-10-29
JP6810693B2 (ja) 2021-01-06
IL252907B (en) 2020-06-30
US10745413B2 (en) 2020-08-18
JP2024037931A (ja) 2024-03-19
MX2021010078A (es) 2021-09-21

Similar Documents

Publication Publication Date Title
BR112017013029A2 (pt) síntese comercialmente viável de cantaridina e de-rivados de cantaridina bioativos
MX2020001278A (es) Sintesis de compuestos de carbamoilpiridona policiclica.
EP3500286A4 (en) N-CARBOXYANHYDRIDE-BASED ELAMIPRETIDE SCALE SYNTHESIS
IN2015DE00625A (pt)
MX2016014765A (es) Incremento del rendimiento utilizando soforolipidos.
ZA201607198B (en) Low ph synthesis of zinc-lysine complex
EP3092514A4 (en) Wide source seismic towing configuration
CL2016003113A1 (es) Productos de escoria granulados y procesos para su producción
BR112017010259A2 (pt) síntese de fischer-tropsch
EP3129343A4 (en) Synthesis of shorter chain polyols
CL2017000645A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
EP3119741A4 (en) An improved process for the synthesis of dimethyl fumarate
BR112016021696A2 (pt) síntese de fischer-tropsch.
WO2018075598A8 (en) SYNTHESIS OF EZH2 INHIBITORS
EP3285875A4 (en) PROCESS FOR SYNTHESIS OF CERAGENES
PL3174849T3 (pl) Synteza pochodnych pirolidyny
EP3177280A4 (en) Synthesis of 2,2,2-trifluoroethanethiol
EP3288560A4 (en) Methods for the synthesis of ceragenins
HK1208220A1 (en) Synthesis method of 9-allylcamptothecin derivatives 9-
TH1501001508A (th) วิธีการสำหรับการผลิตกรด l-อะมิโน
CO7051029A2 (es) Proceso para la preparacion de fenilpropanonas sustituidas
AU356752S (en) Point of sale unit
GB201505319D0 (en) Synchronised variation of source conditions of an atmospheric pressure
TH1601002537A (th) กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง
TH1601000082B (th) วิธีการสำหรับการติดยึดวัตถุตกแต่ง และวัตถุตกแต่ง

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2015, OBSERVADAS AS CONDICOES LEGAIS